CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): An open-label dose-finding and first-in-human study

Aung Naing, Fiona Thistlethwaite, Elisabeth G.E. De Vries, Ferry A.L.M. Eskens, Nataliya Uboha, Patrick A. Ott, Patricia Lorusso, Javier Garcia-Corbacho, Valentina Boni, Johanna Bendell, Karen A. Autio, Manreet Randhawa, Greg Durm, Marta Gil-Martin, Mark Stroh, Alison L. Hannah, Hendrik Tobias Arkenau, Alexander Spira

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): An open-label dose-finding and first-in-human study'. Together they form a unique fingerprint.

Medicine & Life Sciences